Evidence map›Paper›PMID 34729628›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

Pilot-phase PET/CT study targeting integrin α

Ryusuke Nakamoto, Valentina Ferri, Heying Duan, Negin Hatami, Mahima Goel, Jarrett Rosenberg, Richard Kimura, Mirwais Wardak, Tom Haywood, Rowaid Kellow and 4 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02683824 (Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02683824 early_phase1completednot on this map

Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study

TypeinterventionalSponsorStanford UniversityRan2016 to 2022Enrolled21ConditionsHealthy Subject, Pancreatic CarcinomaArmsComputed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  11. Article
  12. Targeting integrin pathways: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2023
    Review
  13. Review
  14. Current status and future perspective of radiopharmaceuticals in China.European journal of nuclear medicine and molecular imaging · 2022
    Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Ryusuke NakamotoDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Valentina FerriDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Heying DuanDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Negin HatamiDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Mahima GoelDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Jarrett RosenbergDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Richard KimuraMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Mirwais WardakMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Tom HaywoodMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Rowaid KellowMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Bin ShenMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Walter ParkDivision of Gastroenterology and Hepatology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.ORCID http://orcid.org/0000-0003-0839-5329
Sanjiv Sam GambhirDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305-5281, USA.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA novel cystine-knot peptide-based PET radiopharmaceutical,

methodsFifteen patients (6 men, 9 women) with histologically confirmed pancreatic cancer were prospectively enrolled and underwent knottin PET/CT between March 2017 and February 2021 (ClinicalTrials.gov Identifier NCT02683824). Vital signs and laboratory results were collected before and after the imaging scans. Maximum standardized uptake values (SUV

resultsThere were no significant changes in vital signs or laboratory values that qualified as adverse events or serious adverse events. At 1 h post-injection, areas of high

conclusion

trial registrationNCT02683824.

Indexed as

Cystine-Knot MiniproteinsPancreatic NeoplasmsAntigens, NeoplasmCystineFemaleHumansIntegrinsMalePeptidesPositron Emission Tomography Computed TomographyRadiopharmaceuticalsTissue DistributionAntigens, NeoplasmCystineCystine-Knot Miniproteinsintegrin alphavbeta6IntegrinsPeptidesRadiopharmaceuticals18F-FP-R01-MG-F2Cystine-knot peptideIntegrin αvβ6Pancreatic cancerPET/CT

Identifiers

PMID34729628
OpenAlexW3211182547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.